

Moderna mRNA Platform

Our mission is to deliver the greatest possible impact to people through mRNA medicine.

President: Stephen Hoge

CEO: Stéphane Bancel

oge moderna

Founded: 2010 Employees: 3,900+ Stock Symbol: MRNA

Toll-Free Phone: 866-MODERNA (866-663-3762)

Phone: (617) 714-6500 Fax: (617) 649-3910

Address: 200 Technology Square

Cambridge, MA 02139

Website: www.modernatx.com

Company Background

ModernaTX, Inc. is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and is allowing for the research and development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. Since our founding in 2010, we have aspired to build the industry's leading mRNA technology platform, the infrastructure to accelerate drug discovery and early development, a rapidly expanding pipeline, and a world class team. Our pipeline includes development candidates for a range of mRNA-based vaccines and therapeutics; drug trials are ongoing for additional candidates progressing toward the clinic, and numerous discovery programs are advancing toward development.

Product Overview

Moderna's mRNA platform, with its speed, scale, and flexibility, is uniquely suited to tackle current and emerging pathogens that threaten global health. Moderna aims to revolutionize medicine and develop potential mRNA treatments in shorter periods of time for previously untreatable and emerging diseases. As its name suggests, mRNA is a messenger. It interacts with other components in cells that help create proteins. As the "workhorses" of cells, proteins are essential for maintaining health and preventing disease. The body makes over 100,000 different kinds

of proteins. Each mRNA strand carries the instructions to make a specific protein. These instructions act as a "blueprint" for other cellular components to build proteins. An mRNA medicine provides the instructions the body needs to make a protein that could potentially prompt your immune system to prevent or treat a specific disease. This may enable the treatment of diseases that cannot be addressed currently with other existing technologies. But mRNA is extremely fragile. So, the mRNA in medicine requires protection in the form of a delivery system, lipid nanoparticles (LNPs), the fatty bubbles we use to deliver mRNA into cells. After it has done its job, the mRNA is broken down in the body given its fragility. Moderna is leveraging the flexibility afforded by our mRNA platform to develop investigational mRNA medicines to address a broad spectrum of viruses and diseases.

Sponsored by Moderna